"The Emergency Environment’s Untapped Potential"

Jan 2011 -

Paola Antonini, M.D., Ph.D., Michael F Murphy, M.D., Ph.D.

Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model

Dec 2010 -

Neil A. Goldenberg, Alex C. Spyropoulos, Jonathan L. Halperin, Craig M. Kessler, Sam Schulman, Alexander G. G. Turpie, Allan M. Skene, Neal R. Cutler, William R. Hiatt a

"Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes"

Dec 2008 -

Allan Skene, Ph.D,Lars Wallentin, M.D., Ph.D., Richard C. Becker, M.D., Andrzej Budaj, M.D., Ph.D., Christopher P. Cannon, M.D., Håkan Emanuelsson, M.D., Ph.D., Claes Held, M.D., Ph.D., Jay Horrow, M.D., Steen Husted, M.D., D.Sc., Stefan James, M.D., Ph.D

Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non–ST-Elevation Acute Coronary Syndromes The MERLIN-TIMI 36 Randomized Trial

Apr 2007 -

David A. Morrow; Benjamin M. Scirica; Ewa Karwatowska-Prokopczuk; et al.

Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non–ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial

Dec 2005 -

David A. Morrow, MD, MPH,a Benjamin M. Scirica, MD,a Ewa Karwatowska-Prokopczuk, MD, PhD,b Allan Skene, PhD,c Carolyn H. McCabe, BS,a and Eugene Braunwald, MDa for the MERLIN-TIMI 36 Investigators Boston, MA; Palo Alto, CA; and Nottingham, UK

"Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes Results From the PROVE IT-TIMI 22 Trial"

Oct 2005 -

Kausik K. Ray, MRCP, MD* Christopher P. Cannon, MD, FACC,* Carolyn H. McCabe, BS,* Richard Cairns, BSC,† Andrew M. Tonkin, MD,‡ Frank M. Sacks, MD,§ Graham Jackson, MD, FRCP,

"Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation"

Mar 2005 -

"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial"

Dec 2004 -

John A Dormandy, Bernard Charbonnel, David J A Eckland, Erland Erdmann, Massimo Massi-Benedetti, Ian K Moules, Allan M Skene, Meng H Tan, Pierre J Lefèbvre, Gordon D Murray, Eberhard Standl, Robert G Wilcox, Lars Wilhelmsen, John Betteridge, Kåre Birkelan

"Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes"

Apr 2004 -

Christopher P. Cannon, M.D., Eugene Braunwald, M.D., Carolyn H. McCabe, B.S., Daniel J. Rader, M.D., Jean L. Rouleau, M.D., Rene Belder, M.D., Steven V. Joyal, M.D., Karen A. Hill, B.A., Marc A. Pfeffer, M.D., Ph.D., and Allan M. Skene, Ph.D.,

Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II

Jan 2001 -

R. P. Giugliano, J. Llevadot, R. G. Wilcox, E. P. Gurfinkel, C. H. McCabe, A. Charlesworth, S. L. Thompson4, E. M. Antman and E. Braunwald

"Intravenous NPA for the treatment of infarcting myocardium early InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction The InTIME-II Investigators"

Dec 1999 -

The InTIME-II Investigators